Funding and incentives for domestic manufacturing. Regulatory and legislative issues related to on-shoring and procurement of sterile injectable products and related medical devices.
2026 · 2nd Quarter (Apr 1 - June 30)
FRESENIUS KABI
Filed by EAST END GROUP, LLC.
Open official filingSource-reported fields
Filing overview
- Type
- 2nd Quarter - Report
- Posted
- Jul 15, 2026
- Income
- $45,000.00
- Expenses
- Not reported
- Registrant
- EAST END GROUP, LLC
- Client
- FRESENIUS KABI
- Filing UUID
- 929a0988-460d-4702-a069-1113f8467982
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Buy America legislation, 232 tariff investigation, regulatory incentives for domestic manufacturing.
Section 232 investigation into pharmaceuticals and unfair trade practices.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.